Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of coniferyl aldehyde in preparation of medicine for treating neonatal necrotizing enterocolitis

A technology for enterocolitis and coniferaldehyde is applied in the application field of coniferaldehyde in the preparation of medicines for the treatment of neonatal necrotizing enterocolitis, so as to achieve the effects of improving NEC and reducing oxidative stress damage

Inactive Publication Date: 2021-07-30
WUXI MATERNAL & CHILD HEALTH HOSPITAL
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Coniferaldehyde (CA) is a potential activator of Nrf2, but there is no relevant research on whether coniferaldehyde can reduce intestinal damage in NEC

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of coniferyl aldehyde in preparation of medicine for treating neonatal necrotizing enterocolitis
  • Application of coniferyl aldehyde in preparation of medicine for treating neonatal necrotizing enterocolitis
  • Application of coniferyl aldehyde in preparation of medicine for treating neonatal necrotizing enterocolitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: Research on the effect of coniferaldehyde on reducing oxidative stress damage in necrotizing enterocolitis

[0024] 1. Materials and Methods

[0025] 1.1 Experimental animals

[0026] Neonatal SD rats were raised in the Medical Experimental Animal Center of Nanjing Medical University, raised in SPF environment, weighed, and randomly divided into 10 rats in the control group, 15 rats in the NEC group, and 15 rats in the coniferaldehyde intervention group.

[0027] 1.2 Drugs and treatment

[0028] The compound coniferaldehyde was purchased from Sigma, USA (purity: 98%), and was dissolved in physiological saline containing 2% DMSO. Coniferaldehyde was administered intraperitoneally once a day to neonatal rats at a dose of 15 mg / kg body weight for 3 days.

[0029] 1.3 Construction of neonatal rat model of necrotizing enterocolitis

[0030] Newborn SD rats were randomly divided into 3 groups after 72 hours of birth: (1) control group: caged with mother mice, f...

Embodiment 2

[0052] Example 2: Research on the Mechanism of Coniferaldehyde in Improving Oxidative Stress Damage of Intestinal Epithelial Cells

[0053] 1. Materials and Methods

[0054] 1.1 Experimental cells

[0055] Human intestinal epithelial cell line (Caco-2) was inoculated into DMEM medium containing 20% ​​fetal bovine serum and 1% double antibody (100U / ml penicillin, 100mg / ml streptomycin), at 37°C, 5% CO2, saturated cultured in a humidity incubator.

[0056] 1.2 Cytopathological modeling and treatment

[0057] Caco-2 cells were transfected with HO-1 short hairpin RNA lentivirus to construct HO-1 gene knock-down (knock-down, KD) stable cell line (Caco-2 HO-1KD cells). Firstly, 5 μM coniferyl aldehyde was pre-stimulated for 8 hours, and then Caco-2 cells and Caco-2 KD cells were stimulated with 5 ug / mL LPS for 24 hours to establish a cell inflammation model and observe the protective effect of coniferaldehyde on cells.

[0058] 1.3 Expression of HMGB1 and inflammatory factors in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines, and particularly relates to application of coniferyl aldehyde in the preparation of a medicine for treating neonatal necrotizing enterocolitis. The coniferyl aldehyde provided by the invention inhibits an HMGB1 transcription function by activating an Nrf2 / HO-1 pathway, and alleviates oxidative stress injury of intestinal epithelial cells, so that the neonatal necrotizing enterocolitis is improved. The effect of the Nrf2 / HO-1 / HMGB1 pathway in NEC intestinal epithelial cell oxidative damage and the intervention effect of coniferyl aldehyde are defined, and a new strategy is provided for prevention and treatment of neonatal necrotizing enterocolitis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of coniferaldehyde in the preparation of medicines for treating neonatal necrotizing enterocolitis. [0002] technical background [0003] Necrotizing enterocolitis (NEC) is the most serious gastrointestinal disease in newborns. The incidence of NEC in live-born infants is 1-3‰, and 90% occurs in premature infants. The incidence rate of NEC in very low birth weight infants in China is 4.5% to 8.7%, and the mortality rate is 20% to 30%. The mortality rate of NEC in extremely low birth weight infants is as high as 30% to 50.9%. In recent years, with the widespread clinical application of prenatal glucocorticoids, postnatal pulmonary surfactant, and early non-invasive assisted ventilation, the survival rate of neonates, especially premature infants, has been continuously improved, but NEC is still the leading cause of neonatal death. One of the most important ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/11A61P1/00
CPCA61K31/11A61P1/00
Inventor 余仁强姜善雨陈爱玲张岩
Owner WUXI MATERNAL & CHILD HEALTH HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com